All IndicationsOncologyPhase 2Phase 2Phase 2Phase 2Phase 2Phase 2Phase 2
🎗️
Advanced Solid Tumor
6
Companies
7
Drug Programs
0
Phase 3
0
Upcoming PDUFAs
Competitors
LTRN
Lantern Pharma Inc.
LP-184
BNTX
BioNTech SE
BNT3212
INCY
Incyte Corporation
INCB099280
BNTX
BioNTech SE
BNT326
ANRO
Alto Neuroscience, Inc.
LM-302 Injection
IMGN
ImmunoGen, Inc.
IMGC936
MRK
MERCK
ANV600
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| LTRN Lantern Pharma Inc. | LP-184 | Phase 2 | — | — | — |
| BNTX BioNTech SE | BNT3212 | Phase 2 | — | — | — |
| INCY Incyte Corporation | INCB099280 | Phase 2 | — | — | — |
| BNTX BioNTech SE | BNT326 | Phase 2 | — | — | — |
| ANRO Alto Neuroscience, Inc. | LM-302 Injection | Phase 2 | — | — | — |
| IMGN ImmunoGen, Inc. | IMGC936 | Phase 2 | — | — | — |
| MRK MERCK | ANV600 | Phase 2 | — | — | — |
Development Stage Distribution
Phase 2
7
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.